News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Faces New Competitive Threat to Chantix; Sopharma's Generic Works Just as Well in Early Studies



9/29/2011 7:25:59 AM

Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived.

A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and much cheaper than alternative products used by smokers seeking to quit, such as Champix.

Read at Financial Times
Read at Fox News
Read at WebMD
Read at ABC News
Read at Business Week


comments powered by Disqus
 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES